Chromium Supplementation for Menstrual Cycle-Related Mood Symptoms
Chromium Supplementation for Menstrual Cycle-Related Mood Symptoms
复制标题
DOI：
10.3109/19390211.2013.830678
复制
发表时间：
2013-12-01
影响因子：
2.5
通讯作者：
McLeod, Malcolm N.
中科院分区：
文献类型：
--
作者：
Brownley, Kimberly A.;Girdler, Susan S.;McLeod, Malcolm N.
背景：经前焦虑症 (PMDD) 困扰着 7% 的育龄妇女，导致人际关系受损、整体生活质量下降，以及与其他主要精神疾病一样的残疾调整生命年损失。大约 50% 的经前抑郁症女性对药物治疗的反应不足。目的：本研究的目的是评估一种新方法——短期补充铬——对月经周期相关情绪和身体症状的影响。方法：在私人临床环境中对 5 名女性进行单盲研究（其中 2 名女性因难治性月经相关症状而被转诊）； 6 名女性在大学临床研究环境中完成了铬加安慰剂与铬加舍曲林的双盲交叉研究。从周期中期到月经开始，每隔 1 个月进行一次治疗。症状评级通过自我报告、使用每日症状检查表以及临床评估、使用汉密尔顿抑郁精神病评定量表（HAM-D）和临床总体印象（CGI）量表来获得。结果：总体而言，铬治疗与大多数参与者的情绪症状减轻和整体健康满意度提高相关。在某些情况下，单独使用铬与显着的临床改善有关；在其他情况下，铬加抗抑郁药比单独使用铬或单独使用抗抑郁药带来更大的改善。结论：这些初步观察结果表明，对于患有明显月经周期相关症状的女性来说，铬可能是一种有用的单一疗法或辅助疗法。需要更大规模的对照研究来评估铬治疗对该患者群体的疗效。
Background: Premenstrual dysphoric disorder (PMDD) afflicts similar to 7% of reproductive-age women resulting in impaired relationships, diminished overall quality of life, and disability-adjusted life years lost on par with other major psychiatric disorders. Response to pharmacological treatment is inadequate in similar to 50% of women with PMDD. Objective: The goal of the present study is to evaluate the effects of a novel approach-short-term chromium supplementation-on menstrual cycle-related mood and physical symptoms. Methods: Five women were studied under single-blind conditions in a private clinical setting (2 of them were referred specifically for treatment-resistant menstrual-related symptoms); 6 women completed a double-blind crossover study of chromium plus placebo versus chromium plus sertraline in a university clinical research setting. Treatments were administered from mid-cycle to onset of menses in 1-month intervals. Symptom ratings were obtained by self-report, using daily symptom checklists, and by clinical assessment, using the Hamilton Psychiatric Rating Scale for Depression (HAM-D) and the Clinical Global Impressions (CGI) scale. Results: Overall, chromium treatment was associated with reduced mood symptoms and improved overall health satisfaction in most participants. In some cases, chromium alone was associated with marked clinical improvement; in others, chromium plus an antidepressant resulted in greater improvement than either chromium alone or an antidepressant alone. Conclusion: These preliminary observations suggest that chromium may be a useful monotherapy or adjunctive therapy for women suffering from significant menstrual cycle-related symptoms. Larger, controlled studies are needed to evaluate the efficacy of chromium treatment in this patient population.